4/2
08:13 am
abus
Moderna (NasdaqGS:MRNA) Faces Legal Spotlight Affecting Investor Sentiment with -8% Dip Over Last Month [Yahoo! Finance]
Low
Report
Moderna (NasdaqGS:MRNA) Faces Legal Spotlight Affecting Investor Sentiment with -8% Dip Over Last Month [Yahoo! Finance]
3/29
02:07 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/28
08:41 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
Medium
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
3/27
07:30 am
abus
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Low
Report
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
3/13
10:15 am
abus
Moderna (NasdaqGS:MRNA) Up 11% Despite Patent Lawsuit Challenges [Yahoo! Finance]
Low
Report
Moderna (NasdaqGS:MRNA) Up 11% Despite Patent Lawsuit Challenges [Yahoo! Finance]
3/13
02:08 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/7
01:08 pm
abus
Moderna (NasdaqGS:MRNA) Rises 10% Despite US$1 Billion Revenue Drop Prediction [Yahoo! Finance]
Low
Report
Moderna (NasdaqGS:MRNA) Rises 10% Despite US$1 Billion Revenue Drop Prediction [Yahoo! Finance]
3/5
02:04 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/3
09:15 am
abus
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Low
Report
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
3/3
09:15 am
abus
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Low
Report
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
2/25
11:05 pm
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/25
09:34 am
abus
Early Warning Report Issued Pursuant to National Instrument 62-103: Roivant announces Resignation and Replacement of Arbutus Board [Yahoo! Finance]
Medium
Report
Early Warning Report Issued Pursuant to National Instrument 62-103: Roivant announces Resignation and Replacement of Arbutus Board [Yahoo! Finance]
2/25
08:04 am
abus
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO [Yahoo! Finance]
Low
Report
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO [Yahoo! Finance]
2/25
07:00 am
abus
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
Medium
Report
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
1/21
08:12 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Neutral
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.